RxDoctor Payments Data
★ My doctorsLook up a doctor →

Karina Marianne Torralba

Rheumatology · Los Angeles, CANPI 1588671176

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AstraZeneca at 35.6% of the total. Reporting peaked in 2024 at $58,260 and has fallen 99.7% since, to $166 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$142,284in general payments, 2019–2025

Across 252 payments — averaging $564.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$51K
  • Sanofi$18K
  • Aurinia Pharma U.S., Inc.$17K
  • Amgen$15K
  • Gilead$7K
  • Novartis$7K
  • plus $26K from 14 others
$490,920in research payments, 2019–2025

Across 58 payments — averaging $8464.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$248K
  • GSK$87K
  • Astrazeneca UK Limited$69K
  • Amgen$33K
  • AstraZeneca$24K
  • Janssen Research & Development, LLC$18K
  • plus $11K from 1 others

What the payments were for

  • Consulting fees$54,23438%
  • Speaking & faculty fees$62,36144%
  • Travel & lodging$15,49811%
  • Food & beverage$10,1457%
  • Education$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)68$50,655
Sanofi18$18,248
Aurinia Pharma U.S., Inc.22$16,972
Amgen(2 entities)28$15,486
Gilead14$7,340
Novartis12$7,338
GSK21$6,954
Boehringer Ingelheim6$6,251
Janssen Scientific Affairs, LLC9$2,757
Johnson & Johnson10$2,362
Fresenius Kabi USA, LLC2$2,276
Cardinal Health 108 LLC11$2,255
UCB, Inc.6$2,176
AbbVie17$672
Genentech USA, Inc.2$206
Mallinckrodt Hospital Products Inc.1$150
Radius Health, Inc.2$107
Sandoz1$30
Pfizer1$27
Sobi, Inc1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,284 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib16$99,462
Hydroxychloroquine Sulfate16$824
MethotrexateMethotrexate Sodium17$320
Leucovorin Calcium11$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$672$99,46216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 rheumatology providers in California.

Other rheumatology in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →